Catalyst
Slingshot members are tracking this event:
AMAG Pharmaceuticals' (AMAG) Makena approved as treatment to reduce preterm birth
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AMAG | Community voting in process | |||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 14, 2018
Occurred Source:
https://globenewswire.com/news-release/2018/02/14/1348440/0/en/AMAG-Pharmaceuticals-Announces-FDA-Approval-of-Makena-hydroxyprogesterone-caproate-injection-Subcutaneous-Auto-Injector-to-Reduce-the-Risk-of-Preterm-Birth-in-Certain-At-Risk-Women.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Makena, Fda Review, Preterm Birth
